We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Bioventix Plc | LSE:BVXP | London | Ordinary Share | GB00B4QVDF07 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
25.00 | 0.57% | 4,375.00 | 4,300.00 | 4,450.00 | 4,375.00 | 4,375.00 | 4,375.00 | 1,477 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Coml Physical, Biologcl Resh | 12.82M | 8.37M | 1.6071 | 27.22 | 227.91M |
Date | Subject | Author | Discuss |
---|---|---|---|
18/12/2013 18:08 | An odd announcement. Kim Tan leaves the board with no explanation and no notice (at least, none to shareholders that I know of). Nigel Martin | gnnmartin | |
04/10/2013 11:36 | Now the results data has been updated for BVXP on Stocko pedia, it is today appearing on the Philip Fisher Growth Screen, which requires a stock to have: A 5yr CAGR > median Sales growth streak (3 yrs consecutive growth) Net margin > median PEG < 0.5 hxxp://www.stock opedia.co.uk/checkli Now for Peter to get out there and tell the story, and help liquidity in the stock pick up. | strollingmolby | |
01/10/2013 10:29 | Possible meeting with CEO Peter Harrison this afternoon in London West End at 4pm. If you would like to attend please email leon@boros.co.uk | boros10 | |
26/9/2013 23:45 | A very strong performance in H2 - real momentum developing now from royalties linked to the Vitamin D anti-bodies with further growth expected. All positive, however, as revenues become increasingly skewed to royalties linked to the product sales of its customers which the Company only discovers after the period end - the visibility of earnings is declining and debtors are starting to rise. The Company also has no real way of checking whether its customers are being honest when they report sales. This might limit growth in countries like China not known for tranparency which might be the reason why anti-body sales are growing but royalties still lag in the people's republic. Overall, shareholders should be delighted though. Peter Harrison, CEO continues to deliver on his promises and we should see 20% compound earnings growth for some years to come. A strong buy even after today's big increase but you won't find it easy to get hold of any stock! | boros10 | |
26/9/2013 21:59 | I've updated the six-month segment data for EPS and dividends in the header, and this is showing a very solid growth trend. Annualised it looks like this: 2011 2012 2013 2-yr change Revenue (£k) 1,974 2,384 2,706 +37.1% Net profit (£k) 884 1,237 1,521 +72.1% EPS (p) 17.59p 24.62p 30.28p +72.1% Working cap (£k) 2,185 2,874 3,764 +72.3% Dividend 11p 12.1p 14.57p +32.5% Cash (£k) 1,532 2,179 2,586 +68.8% And with an operating margin of 56%. Springhill must be kicking themselves... | strollingmolby | |
26/9/2013 16:27 | Bioventix - Preliminary audited results for the year ended 30 June 2013 Click the link to listen | sammy_smith | |
26/9/2013 13:06 | Yes, agreed, Nigel - very solid results! PS just noticed on my Bloomberg app, the share price has shot up - seems someone has just paid 450p... Latest Trades 26/09/2013 12:24 500 @ 450 26/09/2013 11:12 1,000 @ 385 26/09/2013 11:12 1,000 @ 385 26/09/2013 11:06 1,000 @ 380 26/09/2013 11:05 1,000 @ 355 26/09/2013 11:00 1,000 @ 350 26/09/2013 09:13 1,000 @ 345 | strollingmolby | |
26/9/2013 10:48 | Very satisfactory full year results: * Revenues have grown by 14% compared with the year to 30 June 2012 * Profit after tax increased by 23% compared with the year to 30 June 2012 * Cash balances of GBP2.585m at 30 June 2013 (GBP2.179m at 30 June 2012) * Dividend declared of 8.77p (2012: 7.26p) plus "The continued excellent performance of the company in a globally competitive market for antibodies is very satisfying. A PE of 11.5 at 345p, plus a dividend yield of about 4.5% and good growth prospects. Nigel Martin PS. StrollingMolby you were impressively quick to update the header! | gnnmartin | |
07/9/2013 14:15 | I make the PEG to be 0.13 taking the average of the last 5 years EPS growth as a guide for next years growth | 99matti99 | |
21/8/2013 16:13 | Qualifies for ISA under new rules. I put some in mine today. From the ISDX site: 'ISA eligibility consultation: Following recent amendments by the Government to the ISA Regulations 1998 which came into force on 5 August 2013, ISDX is delighted to confirm that shares admitted to trading on its ISDX Growth Market (a Recognised Stock Exchange) are now qualifying investments for stocks and shares ISAs.' I need to do a bit more research but like what i see so far (obviously, just bought some!). Appears to be in the same game as Abcam (LSE:ABC) which is now just short of a billion pound company. Can comparisons be drawn? And then there were 3.........;-) | 99matti99 | |
11/7/2013 12:40 | Confirmation of SpringHill's exit last week: SHAREHOLDER NOTIFICATION 11 JULY 2013 The Company has received notification that SpringHill Bioventures Sdn Bhd ("SpringHill") sold 2,295,000 ordinary shares in Bioventix plc on 28 June 2013. As a result SpringHill has ceased to be a shareholder in Bioventix plc. | strollingmolby | |
03/7/2013 23:08 | Thanks, now I see the large trade/s on the ISDX page (would have liked to participate at 260p) - didn't see it earlier. My mistake on the 600k+ volume on this site, had misread it as '000s when in fact the ISDX page shows 625 shares... Its a shame ADVFN have messed up the site for non-premium users, and don't currently allow them to tailor their threads - if this changes in future I'll work on the header and bring a graph and other details in. | strollingmolby | |
03/7/2013 21:06 | Sorry, I didn't realise you were talking about he trade reports. The large one from Friday appears on the ISDX page - not sure why there are two similar sizes - probably just to stages in the deal. Where do you see the 600k trade? | briangeeee | |
03/7/2013 20:02 | Well spotted, I can't see the 2,295,000 share volume yet. (I can see >600k yesterday) Should see BVXP drop off SpringHill's investee company list in due course if so hxxp://www.springhil | strollingmolby | |
03/7/2013 19:49 | I'm just assuming they sold fully because the reported size matched their holding. Last Friday's trade was, I think, prepared over a few weeks. A friend let me know early last week, so a few of us participated in non-notifiable sizes. Apart from Springhill themselves, there may be other large holders yet to report. It's positive for the company that the Springhill overhang is now clear without being dripped into the market, and hopefully it will generate a little more liquidity in future. | briangeeee | |
03/7/2013 19:06 | Hi Brian - good to see I'm not talking to myself here! Where did you hear about the Friday trade? | strollingmolby | |
03/7/2013 19:04 | I think Springhill sold out completely on Friday. There must be some more announcements to come. | briangeeee | |
03/7/2013 17:34 | Henderson Global Investors appear on the register today with 26.76% - does this contain the holding that Miton manage in the Henderson Fledgling trust, or has HGI bought from SpringHill....?? Hmmmm... | strollingmolby | |
26/3/2013 15:16 | Just made a maiden purchase in these, which was bloody difficult! The interims are due to be released this week - will be interesting to see the progress against the prior year comparables as well as H2 to Jun-12. | strollingmolby |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions